Risk factors for severe infection and mortality In patients with COVID ‐19 in patients with multiple myeloma and AL amyloidosis

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

(2022) Jennifer Hammond et al.   NEW ENGLAND JOURNAL OF MEDICINE

The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review

(2022) Ibrahim Mohammed et al.   Human Vaccines & Immunotherapeutics

Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis

(2022) Ainsley Ryan Yan Bin Lee et al.   BMJ-British Medical Journal

Quantitative SARS-CoV-2 anti-spike responses to Pfizer–BioNTech and Oxford–AstraZeneca vaccines by previous infection status

(2021) David W. Eyre et al.   CLINICAL MICROBIOLOGY AND INFECTION

The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment

(2021) Evangelos Terpos et al.   Blood Cancer Journal

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

(2021) Angélica Jayk Bernal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study

(2021) Katia J Bruxvoort et al.   BMJ-British Medical Journal

COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network

(2021) Heinz Ludwig et al.   Lancet Haematology

Neutralizing Antibody Testing in Patients With Multiple Myeloma Following COVID-19 Vaccination

(2021) Evangelos Terpos et al.   JAMA Oncology

Real‐world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID‐19 disease) in patients with Multiple Myeloma receiving systemic anti‐cancer therapy.

(2020) Gordon Cook et al.   BRITISH JOURNAL OF HAEMATOLOGY

Severe Covid-19

(2020) David A. Berlin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Remdesivir for the Treatment of Covid-19 — Preliminary Report

(2020) John H. Beigel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical characteristics and outcome of multiple myeloma patients with concomitant COVID-19 at Comprehensive Cancer Centers in Germany

(2020) Monika Engelhardt et al.   HAEMATOLOGICA

A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward

(2020) Bo Wang et al.   Journal of Hematology & Oncology

Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM)

(2020) Matthew Ho et al.   LEUKEMIA

Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality

(2020) Joaquín Martínez-López et al.   Blood Cancer Journal

Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set

(2020) Ajai Chari et al.   BLOOD

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

(2020) Lindsey R. Baden et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients

(2019) Kristine A. Frerichs et al.   HAEMATOLOGICA